IGC Pharma Stock Discussion

$IGC Pharma (IGC.US)$ com boy move🚀🚀🚀

$IGC Pharma (IGC.US)$ Alzheimar Pm play.

$IGC Pharma (IGC.US)$
IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease
IGC Pharma (NYSE American: IGC) has announced promising preclinical research on IGC-1C, a novel small-molecule modulator. The findings reveal that IGC-1C targets tau protein phase separation, offering new possibilities for treating neurodegenerative diseases.
Additionally, IGC-1C has been identified as a potential GLP-1 receptor agonist, showing promise for weight...

$IGC Pharma (IGC.US)$ IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease

$IGC Pharma (IGC.US)$ Reuters· 1 min ago
IGC Pharma: Expands Drug Portfolio to Metabolic Disorders With IGC-1a, Potential New GLP-1 Agonist

$IGC Pharma (IGC.US)$ Reuters· 1 min ago
Preclinical Analyses of Tgr-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile

$IGC Pharma (IGC.US)$
Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
IGC Pharma has announced promising preclinical data for its drug candidate TGR-63, targeting Alzheimer’s disease. Studies indicate that TGR-63 can cross the blood-brain barrier, a critical challenge in treating Alzheimer's, as confirmed through mass spectrometry and an octanol-water assay. The drug also demonstrated a favorable safety profile, with no adverse effects observed i...

$IGC Pharma (IGC.US)$ Hedge Fund Settles At $2.25M With SEC For Exposed Short Seller Deal, 2 Cannabis Stocks Affected
Benzinga· 3 mins ago
Anson Funds agreed to a $2.25 million settlement with the Securities and Exchange Commission (SEC) over a secret relationship with a short seller affecting two cannabis companies. The SEC found that while Anson Funds disclosed its short position strategy to investors, it did not reveal its collaboratio...

$IGC Pharma (IGC.US)$ IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1! Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's

$IGC Pharma (IGC.US)$
IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1